在患有高体脂百分比的儿童中,PBMC蛋白质组发生变化
Maya Petek1, Tjaša Hertiš Petek2, Uroš Potočnik3,4,5
1Faculty of Medicine, University of Maribor, Maribor, Slovenia.
Scientific reports
|November 19, 2025
概括
儿童肥胖与血液细胞内的蛋白质变化有关,特别是那些参与新陈代谢和炎症的蛋白质. 身体脂肪百分比是儿童肥胖症中这些蛋白质基因变化的关键指标.
科学领域:
- 儿科内分泌学 儿科内分泌学
- 蛋白质组学是指蛋白质组学.
- 公共卫生 公共卫生
背景情况:
- 儿童肥胖是一个日益严重的公共卫生问题.
- 过多的脂肪组织与炎症和代谢功能障碍有关.
- 对外围血液单核细胞 (PBMC) 的蛋白质组分析可以识别与疾病相关的变化.
研究的目的:
- 为了确定肥胖儿童的PBMC中的蛋白质组失调.
- 研究与儿童肥胖症炎症和代谢功能障碍相关的途径.
- 为了将蛋白质变化与身体成分指标相关联.
主要方法:
- 分析了71名体重状况不同的儿童和青少年 (5-18岁) 的PBMC溶解物.
- 使用生物电阻分析测量身体成分.
- 使用纳米电子喷涂液体染色学结合联质谱学确定蛋白质丰度.
主要成果:
- 鉴定出148种与身体脂肪百分比显著相关的蛋白质,控制性别,年龄和白细胞数量.
- 与肥胖相关的蛋白质变化包括CutA,GTPase活性蛋白和线粒体蛋白.
- 身体脂肪百分比比较好地解释了蛋白质组变化,而不是仅仅基于身高和体重的指标.
结论:
- 对PBMC的蛋白质组分析揭示了肥胖儿童的显著变化.
- 身体成分分析,特别是身体脂肪百分比,对于解释小儿肥胖的蛋白质组发现至关重要.
- 这些发现突出了儿童肥胖中代谢功能障碍和炎症的潜在生物标志物.
相关概念视频
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
228
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
228
Pharmacokinetics in Pediatric Patients: Drug Distribution
247
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
247
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
162
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
162
Pharmacokinetics in Pediatric Patients: Drug Metabolism
179
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
179
Obesity
1.1K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.1K


